23 related articles for article (PubMed ID: 8154313)
1. Paget's disease of bone: diagnosis and management.
Hosking D; Meunier PJ; Ringe JD; Reginster JY; Gennari C
BMJ; 1996 Feb; 312(7029):491-4. PubMed ID: 8597686
[No Abstract] [Full Text] [Related]
2. Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium.
Price RI; Gutteridge DH; Stuckey BG; Kent GN; Retallack RW; Prince RL; Bhagat CI; Johnston CA; Nicholson GC; Stewart GO
J Bone Miner Res; 1993 Feb; 8(2):209-17. PubMed ID: 8442439
[TBL] [Abstract][Full Text] [Related]
3. Alterations in vitamin D metabolites during treatment of Paget's disease of bone with calcitonin or etidronate.
Devlin RD; Gutteridge DH; Prince RL; Retallack RW; Worth GK
J Bone Miner Res; 1990 Nov; 5(11):1121-6. PubMed ID: 2125401
[TBL] [Abstract][Full Text] [Related]
4. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
[TBL] [Abstract][Full Text] [Related]
5. Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD.
Papapoulos SE; Harinck HI; Bijvoet OL; Gleed JH; Fraher LJ; O'Riordan JL
Bone Miner; 1986 Feb; 1(1):69-78. PubMed ID: 3508718
[TBL] [Abstract][Full Text] [Related]
6. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
[TBL] [Abstract][Full Text] [Related]
7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
8. Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.
Polyzos SA; Anastasilakis AD; Makras P; Terpos E
Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):519-24. PubMed ID: 21811962
[TBL] [Abstract][Full Text] [Related]
9. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Fitton A; McTavish D
Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates: an overview with special reference to alendronate.
Vasikaran SD
Ann Clin Biochem; 2001 Nov; 38(Pt 6):608-23. PubMed ID: 11732644
[TBL] [Abstract][Full Text] [Related]
11. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
Devlin RD; Retallack RW; Fenton AJ; Grill V; Gutteridge DH; Kent GN; Prince RL; Worth GK
J Bone Miner Res; 1994 Jan; 9(1):81-5. PubMed ID: 8154313
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
